German Appeals Court Rules in Favor of AGA Medical in Patent Infringement Lawsuit Against Occlutech

Minneapolis (ots/PRNewswire) -

AGA Medical Holdings, Inc. ("AGA Medical" or "AGA") announced
today that a German appeals court has ruled in its favor in a patent
infringement proceeding against Occlutech GmbH, headquartered in
Jena, Germany. The lawsuit was brought by AGA in 2006 in Dusseldorf,
Germany seeking to enjoin Occlutech from infringing the German part
of AGA's European patent (EP 0 808 138) and for damages resulting
therefrom. The amount of damages and other remedies will be decided
in enforcement proceedings in the near future.

Following the District Court's decision in July 2007, requiring
destruction of the infringing product and the entry of an injunction,
Occlutech appealed the ruling and introduced its Figulla N product,
which it maintained was non-infringing. The appeals court not only
affirmed the findings of the District Court, but also found that the
Figulla N occluder was not materially different from Occlutech's
original product, and thus subject to the injunction and resulted in
damages to AGA Medical. The appeals court further has declined
Occlutech's request to stay the infringement proceedings in light of
parallel invalidity proceedings pending at the Federal Patents Court.

"The positive ruling of the German appeals court confirms our
rightful ownership of this technology and supports the original
ruling that Occlutech's products are a clear infringement on our
intellectual property," said John Barr, President and CEO of AGA
Medical. "We are pleased with the outcome and will continue to
vigilantly defend our intellectual property rights throughout the
world."

About AGA Medical

AGA Medical, based in Plymouth, Minnesota, is a leader in
developing interventional devices for the minimally invasive
treatment of cardiovascular defects and peripheral vascular disease.
Founded in 1995 by Dr. Kurt Amplatz, a former professor and
researcher at the University of Minnesota Department of Radiology,
AGA Medical develops and commercializes devices for a range of
structural heart repair and circulatory conditions. Several of these
devices have been major innovations in the treatment of the most
common congenital "holes in the heart", such as atrial septal defects
and patent foramen ovales.

More than 700 articles have been published in medical literature
that support the benefits of AGA Medical devices, including improved
patient outcomes, reduced length of stay, and accelerated recovery
times for the patient. AGA Medical devices have received regulatory
approval and are marketed in 101 countries. For more information,
visit http://www.amplatzer.com.

ots Originaltext: AGA Medical Holdings, Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Kate Ferguson, +1-415-946-1059, kferguson@wcpglobal.com, or Aimee
Corso, +1-503-855-4502, acorso@wcpglobal.com, both of WeissComm
Partners, for AGA Medical Holdings, Inc.